STOCK TITAN

G1 Therapeutics Inc - GTHX STOCK NEWS

Welcome to our dedicated news page for G1 Therapeutics (Ticker: GTHX), a resource for investors and traders seeking the latest updates and insights on G1 Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect G1 Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of G1 Therapeutics's position in the market.

Rhea-AI Summary
G1 Therapeutics, Inc. presented preliminary results from its Phase 2 study of trilaciclib in patients with triple-negative breast cancer. Trilaciclib showed potential in reducing adverse events associated with sacituzumab govitecan-hziy, with a greater than 50% reduction in events such as neutropenia, anemia, and diarrhea. Patients with PD-L1(+) tumors had a higher response rate. Overall survival results are expected in Q1 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.02%
Tags
-
Rhea-AI Summary
G1 Therapeutics, Inc. provided a corporate and financial update for Q1 2023. Net COSELA revenue grew by 18% compared to Q4 2022, and vial volume increased by 21%. The company strengthened its balance sheet through a monetization deal with Simcere, securing additional financing. The timing for the interim overall survival analysis of the pivotal Phase 3 trial in metastatic triple negative breast cancer (TNBC) has been updated to Q1 2024. G1 also completed enrollment in a Phase 2 trial of trilaciclib in combination with an antibody drug conjugate (ADC) in patients with metastatic TNBC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.68%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.57%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.8%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.38%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.02%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.17%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.81%
Tags
none
G1 Therapeutics Inc

Nasdaq:GTHX

GTHX Rankings

GTHX Stock Data

237.51M
43.59M
11.68%
30.15%
5.28%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Research Triangle Park

About GTHX

g1 therapeutics is a clinical-stage company developing small-molecule therapies to address significant unmet needs in oncology. the company is leveraging its proprietary kinase drug discovery platform to advance a pipeline of best-in-class compounds and first-in-class drug candidates.